What are the NCCN guidelines for primary induction therapy in patients with multiple myeloma (MM) who are candidates for transplantation?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The NCCN guidelines recommend combining induction therapy for MM with bone-targeted treatment (bisphosphonates or denosumab) and supportive care as necessary. For primary induction therapy in patients with MM who are candidates for transplantation, NCCN guidelines recommend the following as preferred regimens [2] :

  • Bortezomib/lenalidomide/dexamethasone (category 1)
  • Bortezomib/cyclophosphamide/dexamethasone (preferred initial treatment in patients with acute renal insufficiency)

Other recommended regimens, according to the NCCN, are as follows:

  • Carfilzomib/lenalidomide/dexamethasone
  • Daratumumab/lenalidomide/bortezomib/dexamethasone
  • Ixazomib/lenalidomide/dexamethasone (category 2B)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!